Adaptimmune Reports First Quarter 2019 Financial Results
06 mai 2019 07h30 HE
|
Adaptimmune Therapeutics plc
- Clinical update issued in a separate announcement - - Financial guidance updated: funded into Q3 2020 - PHILADELPHIA and OXFORD, United Kingdom, May 06, 2019 (GLOBE NEWSWIRE) -- Adaptimmune...
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
06 mai 2019 07h00 HE
|
Adaptimmune Therapeutics plc
- Partial responses in 4 out of 5 synovial sarcoma patients treated with ~10 billion cells, with tumor shrinkage in nearly all assessed synovial sarcoma patients in the ADP-A2M4 pilot study - ...
Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
02 mai 2019 07h00 HE
|
Adaptimmune Therapeutics plc
- Data show strong progress with off-the-shelf program demonstrating T-cell differentiation from stem cells (hiPSC) in a serum-free process without the addition of mouse stromal cells - - Lentiviral...
Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019
01 mai 2019 08h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and...
Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
18 avr. 2019 16h01 HE
|
Adaptimmune Therapeutics plc
- Presentation to include overview of substantial progress of Adaptimmune’s off-the-shelf SPEAR T-cell platform - - Data will show that hiPSC-derived allogeneic SPEAR T-cells have a T-cell phenotype...
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
02 avr. 2019 08h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, April 02, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data...
CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
27 févr. 2019 12h05 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Adaptimmune Therapeutics plc (Nasdaq:ADAP), please note that...
Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
27 févr. 2019 07h29 HE
|
Adaptimmune Therapeutics plc
- On track for clinical data update from trials in multiple solid tumors at the Q1 2019 earnings update call in May - - Completed initial safety cohorts for ADP-A2M10 (MAGE-A10) in lung and triple...
Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
07 févr. 2019 08h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for...
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
07 janv. 2019 07h30 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety...